Two epilepsy self-management programs test with enhanced usual care
Official title: Economic Evaluation of Managing Epilepsy Well (MEW) Network Epilepsy Self-Management Programs
Run by NYU Langone Health · NCT07087821 · Data updated 2026-11-12
This study tests whether UPLIFT or PACES help adults with epilepsy improve quality of life and reduce depressive symptoms compared with enhanced usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 108 (estimated) |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 2 sites (Brooklyn, New York and 1 other locations) |
| Status | Recruiting |
| Started | September 16, 2025 |
| Main results expected | September 29, 2027 |
| Study ends | September 29, 2027 |
| Registry record updated | May 29, 2026 |
| Trial ID | NCT07087821 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older with epilepsy for at least one year, fluent in English (and Spanish for UPLIFT) and with elevated depressive symptoms (PHQ-9 ≥ 10) for the UPLIFT arm.
✕Probably not a fit
Individuals with severe depressive symptoms (PHQ-9 ≥ 20), active suicidal ideation, active psychotic disorders, or significant cognitive impairment may not benefit from these programs.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Two parallel randomized controlled trials will compare UPLIFT and PACES, each against enhanced usual care, in adults with epilepsy across NYU sites. The trials will look at quality of life, depressive symptoms, and seizure control over 12 months, plus an economic evaluation using data from both trials and community settings. Participants will have baseline and follow-up assessments at 3, 6, and 12 months to align outcomes for cost-effectiveness analyses. UPLIFT includes both English-speaking and Spanish-speaking components, while PACES is English-speaking only. Eligible participants are adults with epilepsy for at least one year, able to consent, and with elevated depressive symptoms for the UPLIFT arm; exclusions include severe depression, active suicidal ideation, psychotic disorders, or significant cognitive impairment.
Why it matters
Potential benefit: If successful, participants may experience improved quality of life, fewer depressive symptoms, and better management of epilepsy through self-management programs.
How similar studies have gone: Self-management programs for epilepsy have shown promise in improving quality of life and mood in prior studies, but large-scale economic evaluations and implementation in diverse settings are less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) * English-speaking (UPLIFT and PACES) or Spanish-speaking (UPLIFT only). * Diagnosed with epilepsy for at least one year * Able to understand the informed consent and provide consent * Elevated depressive symptoms - Patient Health Questionnaire-9 (PHQ-9) score ≥10; applies to UPLIFT only Exclusion Criteria: * Severe depressive symptoms (score of ≥20 on PHQ-9) * Active suicidal ideation (score of ≥1 on PHQ-9 item #9 or otherwise reported during screening) * Active psychotic disorder (psychiatric diagnosis and/or antipsychotic medications in the electronic health records (EHR) * Significant cognitive impairment (indicated in the EHR or evident during screening)
Where it's running
-
NYU Langone Health - NYU Langone Hospital-Brooklyn
Brooklyn, New York, United States Recruiting -
NYU Langone Health - NYU Comprehensive Epilepsy Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Tanya Spruill, PhD — NYU Langone Health
- Study coordinator: Tanya Spruill, PhD
- Email: Tanya.Spruill@nyulangone.org
- Phone: 646-501-3429
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
RAP-219 long-acting injectable safety and PK study in healthy adults
This early study tests RAP-219-LAI in healthy adults to see how it behaves in the body and whether it is safe and tolerable.
-
Why People with Epilepsy Get More Infections
This study tests whether anti-seizure medicines affect immune function and infection risk in people with epilepsy.
-
Long-Term Epilepsy Outcomes in Children After Perinatal Stroke
This study looks at how epilepsy progresses in kids who had a stroke before 28 days old to see how their seizures and syndromes evolve over time.
-
Hypothalamus structure and heart autonomic changes in drug-resistant epilepsy
This study tests whether structural changes in the hypothalamus relate to cardiac autonomic dysfunction in adults with drug-resistant epilepsy.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Advanced 7T fMRI for brain function in epilepsy and brain injuries
This study tests ultra-high-field brain scans at 7T to see if they can better map brain function in adults with epilepsy or brain lesions and in healthy volunteers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.